drugset / Trial / NCT01153321

Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)

NCT01153321 ↗

Phase 2 Completed 71 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of the study is to find out if AZD2423 can reduce inflammation in the lungs of patients with mild COPD.

Timeline

Start
2010-10
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2423 Unknown 100 mg Oral